A real-world study showed HER2DX guided treatment changes in approximately 48% of HER2-positive breast cancer cases.
The updated guidelines note that patients with stage IV NSCLC who have EGFR exon 19 deletions or exon 21 L858R substitutions can receive osimertinib plus platinum doublet chemotherapy or amivantamab ...
The first patients have been enrolled in the HEROES trial, exploring de-escalation of anti-HER2 therapy in metastatic HER2+ ...
News Medical on MSN11h
IgE antibodies show promise in targeting HER2 cancers resistant to other therapiesAntibody treatment which activates the patient's own immune system against cancer, known as immunotherapy, is increasingly being investigated as an alternative for chemotherapy and radiotherapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback